Gan & Lee Pharmaceuticals. (SHA:603087)

China flag China · Delayed Price · Currency is CNY
60.01
-0.22 (-0.37%)
Apr 29, 2026, 10:25 AM CST
23.15%
Market Cap 35.85B
Revenue (ttm) 3.95B
Net Income (ttm) 1.02B
Shares Out 595.20M
EPS (ttm) 1.73
PE Ratio 34.77
Forward PE 23.34
Dividend 1.50 (2.50%)
Ex-Dividend Date n/a
Volume 1,567,617
Average Volume 6,906,857
Open 59.59
Previous Close 60.23
Day's Range 59.59 - 60.38
52-Week Range 47.58 - 82.25
Beta 0.72
RSI 40.55
Earnings Date Apr 23, 2026

About SHA:603087

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection... [Read more]

Sector Healthcare
Founded 1998
Employees 5,245
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 603087
Full Company Profile

Financial Performance

In 2025, SHA:603087's revenue was 4.05 billion, an increase of 33.06% compared to the previous year's 3.05 billion. Earnings were 1.14 billion, an increase of 86.05%.

Financial Statements

News

There is no news available yet.